The O O
isolates O B_BIO
were O O
tentatively O O
identified O O
as O O
a O O
streptococcal O B_BACTERIUM[BIO]
species O I_BACTERIUM[BIO]
based O O
on O O
the O O
results O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
biochemical O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
tests O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Comparative O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
16S O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
rRNA O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
gene O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
sequencing O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
studies O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
confirmed O O
that O O
the O O
organisms O B_BIO/B_GENE
were O O
members O B_PERSON/B_LOCATION
of O O
the O O
genus O B_BIO/B_MEASURE
Streptococcus O I_BIO/I_MEASURE
, O O
but O O
they O O
did O O
not O O
correspond O O
to O O
any O O
recognized O O
species O B_BIO/B_PERSON
of O O
the O O
genus O B_BACTERIUM[BIO]/B_MEASURE
. O O

The O O
type O O
strain O O
of O O
S B B_BACTERIUM[BIO]/B_LOCATION
. I B_BACTERIUM[BIO]/I_LOCATION
ursoris I B_BACTERIUM[BIO]/I_LOCATION
is O O
NUM B B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
1615 I I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( I I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
T I I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) I I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
= O O
JCM O O
16316 O O
( O O
T O O
) O O
= O O
DSM O O
22768 O O
( O O
T O O
) O O
) O O
. O O

A O O
novel O O
bacterial O O
strain O O
, O O
designated O O
M2T2B15 B B_PROTEIN[GENE]/B_LOCATION
( O O
T O O
) O O
, O O
was O O
isolated O O
from O O
fermented O O
bovine O O
products O O
and O O
was O O
characterized O O
by O O
using O O
a O O
polyphasic O O
approach O O
. O O

Cells O B_BIO/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
were O O
strictly O O
aerobic O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
, O O
Gram O B_BACTERIUM[BIO]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
reaction O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
negative O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
oxidase O B_ENZYME[GENE]
- O O
and O O
catalase O B_ENZYME[GENE]
- O O
positive O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
rods O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
that O O
lacked O O
flagella O B_BACTERIUM[BIO]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
were O O
motile O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
by O O
gliding O O
. O O

16S O O
rRNA O O
gene O O
sequence O O
analysis O O
indicated O O
that O O
strain O O
M2T2B15 B B_MEASURE/B_GENE
( O O
T O O
) O O
was O O
related O O
most O O
closely O O
to O O
Larkinella B B_BIO/B_LOCATION
insperata I I_BIO/I_LOCATION
LMG O O
22510 O O
( O O
T O O
) O O
( O O
94 O O
. O O
4 O O
% O O
similarity O O
) O O
but O O
shared O O
& O O
lt O O
; O O
87 O O
% O O
similarity O O
with O O
other O O
members O O
of O O
the O O
phylum O O
Bacteroidetes O O
. O O

The O O
G O O
+ O O
C O O
content O O
of O O
the O O
DNA O O
of O O
strain O O
M2T2B15 B B_MEASURE/B_PROTEIN[GENE]
( O O
T O O
) O O
was O O
52 O O
& O O
amp O O
; O O
emsp14 O O
; O O
mol O O
% O O
. O O

The O O
type O O
strain O O
is O O
M2T2B15 B B_PROTEIN[GENE]/B_DISEASE
( O O
T O O
) O O
( O O
= O O
KACC O O
14040 O O
( O O
T O O
) O O
= O O
NBRC O O
106324 O O
( O O
T O O
) O O
) O O
. O O

A O O
mesophilic O O
, O O
non O O
- O O
motile O O
, O O
hydrogenotrophic O O
, O O
rod O O
- O O
shaped O O
methanogen O O
, O O
designated O O
M2 B B_PROTEIN[GENE]/B_MEASURE
( I I_PROTEIN[GENE]/I_MEASURE
T I I_PROTEIN[GENE]/I_MEASURE
) I I_PROTEIN[GENE]/I_MEASURE
, O O
was O O
isolated O O
from O O
Holocene O O
permafrost O O
sediments O O
of O O
the O O
Kolyma O O
lowland O O
in O O
the O O
Russian O O
Arctic O O
. O O

Strain O O
M2 B B_GENE/B_MEASURE
( I B_GENE/I_MEASURE
T I B_GENE/I_MEASURE
) I B_GENE/I_MEASURE
grew O O
on O O
H O O
( O O
2 O O
) O O
/ O O
CO O O
( O O
2 O O
) O O
and O O
formate O O
. O O

On O O
the O O
basis O O
of O O
16S O O
rRNA O O
gene O O
sequence O O
comparison O O
with O O
known O O
methanogens O O
, O O
strain O O
M2 B B_MEASURE/B_GENE
( I I_MEASURE/I_GENE
T I I_MEASURE/I_GENE
) I I_MEASURE/I_GENE
was O O
affiliated O O
with O O
the O O
genus O O
Methanobacterium O O
and O O
was O O
most O O
closely O O
related O O
to O O
Methanobacterium B B_BACTERIUM[BIO]
veterum I I_BACTERIUM[BIO]
MK4 I I_BACTERIUM[BIO]
( I I_BACTERIUM[BIO]
T I I_BACTERIUM[BIO]
) I I_BACTERIUM[BIO]
and O O
Methanobacterium B B_PROTEIN[GENE]/B_BACTERIUM[BIO]
bryantii I I_PROTEIN[GENE]/I_BACTERIUM[BIO]
DSM B I_PROTEIN[GENE]/I_BACTERIUM[BIO]
863 I I_PROTEIN[GENE]/I_BACTERIUM[BIO]
( I I_PROTEIN[GENE]/I_BACTERIUM[BIO]
T I I_PROTEIN[GENE]/I_BACTERIUM[BIO]
) I I_PROTEIN[GENE]/I_BACTERIUM[BIO]
( O O
both O O
99 O O
% O O
16S O O
rRNA O O
gene O O
sequence O O
similarity O O
) O O
. O O

However O O
, O O
no O O
significant O O
DNA O O
- O O
DNA O O
relatedness O O
was O O
observed O O
between O O
strain O O
M2 B B_PROTEIN[GENE]/B_MEASURE
( I I_PROTEIN[GENE]/I_MEASURE
T I I_PROTEIN[GENE]/I_MEASURE
) I I_PROTEIN[GENE]/I_MEASURE
and O O
these O O
type O O
strains O O
. O O

We O O
propose O O
that O O
strain O O
M2 B B_PROTEIN[GENE]
( I I_PROTEIN[GENE]
T I I_PROTEIN[GENE]
) I I_PROTEIN[GENE]
represents O O
a O O
novel O O
species O O
, O O
with O O
the O O
name O O
Methanobacterium O O
arcticum O O
sp O O
. O O
nov O O
. O O
, O O
with O O
type O O
strain O O
M2 B B_PROTEIN[GENE]/B_DISEASE
( I I_PROTEIN[GENE]/I_DISEASE
T I I_PROTEIN[GENE]/I_DISEASE
) I I_PROTEIN[GENE]/I_DISEASE
( O O
= O O
DSM O O
19844 O O
( O O
T O O
) O O
= O O
VKM O O
B O O
- O O
2371 O O
( O O
T O O
) O O
) O O
. O O

A O O
novel O O
, O O
hydrogen O O
- O O
and O O
sulfur O O
- O O
oxidizing O O
bacterium O O
, O O
designated O O
strain O O
6C B B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( I I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
T I I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) I I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
was O O
isolated O O
from O O
a O O
hot O O
spring O O
in O O
Graendalur O O
, O O
south O O
- O O
western O O
Iceland O O
. O O

Cells O B_BIO/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
of O O
this O O
organism O B_BIO
were O O
Gram O B_BACTERIUM[BIO]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
reaction O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O O
negative O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
rod O B_BODY_PART_OR_ORGAN_COMPONENT/B_BIO
- O O
shaped O O
and O O
motile O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
. O O

As O O
determined O O
by O O
16S O O
rRNA O O
gene O O
sequence O O
analysis O O
, O O
strain O O
6C B B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( I I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
T I I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) I I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
represents O O
a O O
distinct O O
species O O
belonging O O
to O O
the O O
class O O
Betaproteobacteria B B_BACTERIUM[BIO]
and O O
is O O
most O O
closely O O
related O O
to O O
Thiomonas B B_BACTERIUM[BIO]
intermedia I I_BACTERIUM[BIO]
DSM B I_BACTERIUM[BIO]
18155 I I_BACTERIUM[BIO]
( I I_BACTERIUM[BIO]
T I I_BACTERIUM[BIO]
) I I_BACTERIUM[BIO]
and O O
Thiomonas B B_BACTERIUM[BIO]/B_LOCATION
perometabolis I B_BACTERIUM[BIO]/I_LOCATION
DSM B B_BACTERIUM[BIO]/I_LOCATION
18570 I B_BACTERIUM[BIO]/I_LOCATION
( I B_BACTERIUM[BIO]/I_LOCATION
T I B_BACTERIUM[BIO]/I_LOCATION
) I B_BACTERIUM[BIO]/I_LOCATION
. O O

DNA O O
- O O
DNA O O
hybridization O O
between O O
strain O O
6C B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
( I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
T I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
) I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
and O O
Thiomonas B B_BIO/B_PROTEIN[GENE]
intermedia I B_BIO/I_PROTEIN[GENE]
DSM B B_BIO/I_PROTEIN[GENE]
18155 I B_BIO/I_PROTEIN[GENE]
( I B_BIO/I_PROTEIN[GENE]
T I B_BIO/I_PROTEIN[GENE]
) I B_BIO/I_PROTEIN[GENE]
and O O
Thiomonas B B_BIO/B_GENE
perometabolis I B_BIO/I_GENE
DSM B B_BIO/I_GENE
18570 I B_BIO/I_GENE
( I B_BIO/I_GENE
T I B_BIO/I_GENE
) I B_BIO/I_GENE
gave O O
relatedness O O
values O O
below O O
32 O O
% O O
. O O

These O O
results O O
, O O
together O O
with O O
physiological O O
characteristics O O
, O O
showed O O
that O O
strain O O
6C B B_NUMBER[MEASURE]
( I I_NUMBER[MEASURE]
T I I_NUMBER[MEASURE]
) I I_NUMBER[MEASURE]
represents O O
a O O
novel O O
species O O
within O O
the O O
genus O O
Thiomonas O O
, O O
for O O
which O O
the O O
name O O
Thiomonas B B_BACTERIUM[BIO]
islandica I I_BACTERIUM[BIO]
sp O O
. O O
nov O O
. O O

The O O
type O O
strain O O
is O O
6C B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
( I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
T I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
) I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
( O O
= O O
DSM B B_DISEASE
21436 I I_DISEASE
( I I_DISEASE
T I I_DISEASE
) I I_DISEASE
= O O
JCM B B_MEASURE/B_DISEASE
16107 I I_MEASURE/I_DISEASE
( I I_MEASURE/I_DISEASE
T I I_MEASURE/I_DISEASE
) I I_MEASURE/I_DISEASE
) O O
. O O

Nocardioides B B_NUMBER[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
caricicola I I_NUMBER[MEASURE]/I_DISEASE_ADJECTIVE[DISEASE]
sp I I_NUMBER[MEASURE]/I_DISEASE_ADJECTIVE[DISEASE]
. I I_NUMBER[MEASURE]/I_DISEASE_ADJECTIVE[DISEASE]
nov I I_NUMBER[MEASURE]/I_DISEASE_ADJECTIVE[DISEASE]
. I I_NUMBER[MEASURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O O
an O O
endophytic O O
bacterium O O
isolated O O
from O O
a O O
halophyte O O
, O O
Carex B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BACTERIUM[BIO]
scabrifolia I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BACTERIUM[BIO]
Steud O O
. O O

Strain O O
YC6903 B B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
T O O
) O O
grew O O
optimally O O
at O O
30 O O
^ O O
0C O O
and O O
at O O
pH O O
8 O O
. O O
0 O O
. O O

Phenotypic O O
, O O
phylogenetic O O
and O O
chemotaxonomic O O
data O O
indicated O O
that O O
strain O O
YC6903 B B_NUMBER[MEASURE]/B_PERSON
( O O
T O O
) O O
represents O O
a O O
novel O O
species O O
of O O
the O O
genus O O
Nocardioides O O
, O O
for O O
which O O
the O O
name O O
Nocardioides B B_TIME[MEASURE]/B_DISEASE
caricicola I I_TIME[MEASURE]/I_DISEASE
sp I I_TIME[MEASURE]/I_DISEASE
. I I_TIME[MEASURE]/I_DISEASE
nov I I_TIME[MEASURE]/I_DISEASE
. I I_TIME[MEASURE]/I_DISEASE

The O O
type O O
strain O O
is O O
YC6903 B B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
T O O
) O O
( O O
= O O
KACC O O
13778 O O
( O O
T O O
) O O
= O O
DSM O O
22177 O O
( O O
T O O
) O O
) O O
. O O

The O O
original O O
description O O
of O O
this O O
organism O O
was O O
based O O
on O O
brownish O O
, O O
immotile O O
coccoid O O
cells O O
, O O
which O O
is O O
the O O
predominating O O
stage O O
of O O
C B B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANISM_FUNCTION
. I B_DISEASE_ADJECTIVE[DISEASE]/I_ORGANISM_FUNCTION
velia I B_DISEASE_ADJECTIVE[DISEASE]/I_ORGANISM_FUNCTION
in O O
the O O
culture O O
. O O

Chrysophytes O B_BACTERIUM[BIO]/B_PERSON
dominated O O
the O O
samples O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
in O O
the O O
cold O B_TIME[MEASURE]/B_LOCATION
period O I_TIME[MEASURE]/I_LOCATION
while O O
testate O B_BIO/B_PERSON
amoebae O I_BIO/I_PERSON
( O O
Arcellinida O B_BACTERIUM[BIO]
and O O
Euglyphida O B_BACTERIUM[BIO]
) O O
and O O
a O O
few O B_BIO
other O I_BIO
groups O I_BIO
peaked O O
in O O
summer O B_MEASURE/B_LOCATION
. O O

A O O
few O B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
phylotypes O I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
( O O
such O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
as O O
a O O
cryptomonad O B_SPECIES[BIO]
and O O
a O O
perkinsid O B_BACTERIUM[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
were O O
abundant O B_DISEASE_ADJECTIVE[DISEASE]
at O O
given O O
sampling O O
times O B_MEASURE/B_LOCATION
and O O
then O O
almost O O
disappeared O O
, O O
suggesting O O
bloom O B_LOCATION/B_DISEASE_ADJECTIVE[DISEASE]
- O O
like O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
dynamics O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Accordingly O O
, O O
we O O
analysed O O
mitochondrial O B_GENE/B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
COI O B_GENE/I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
gene O B_GENE/I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
sequences O B_GENE/I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
and O O
nuclear O B_GENE
small O I_GENE
subunit O I_GENE
rDNA O I_GENE
( O O
SSU O B_DISEASE/B_GENE
) O O
sequences O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
from O O
several O B_BIO/B_GENE
morphospecies O I_BIO/I_GENE
of O O
euglyphid O B_BIO
testate O I_BIO
amoebae O I_BIO
( O O
Cercozoa O B_BACTERIUM[BIO]/B_LOCATION
, O O
Rhizaria O B_MEASURE/B_BACTERIUM[BIO]
) O O
in O O
order O B_LOCATION/B_DISEASE
to O O
evaluate O O
the O O
utility O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
these O O
DNA O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
markers O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
for O O
species O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
discrimination O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
and O O
phylogenetic O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
reconstructions O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Linking O O
disease O O
and O O
community O O
ecology O O
through O O
behavioural O O
indicators O O
: O O
immunochallenge O O
of O O
white B B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
footed I I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mice I I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
its O O
ecological O O
impacts O O
. O O

To O O
explore O O
host O O
behavioural O O
response O O
to O O
immune O O
challenge O O
, O O
we O O
exposed O O
wild O O
white B B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_SPECIES[BIO]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
footed I I_SPECIES[BIO]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mice I I_SPECIES[BIO]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
Peromyscus B B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
leucopus I I_PROTEIN[GENE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
to O O
an O O
immunogen O O
from O O
an O O
endemic O O
, O O
zoonotic O O
pathogen O O
, O O
the O O
spirochete O O
Borrelia B B_BACTERIUM[BIO]
burgdorferi I I_BACTERIUM[BIO]
. O O

Only O O
one O O
species O O
, O O
Chaetomium B B_LOCATION/B_DISEASE_ADJECTIVE[DISEASE]
globosum I I_LOCATION/I_DISEASE_ADJECTIVE[DISEASE]
, O O
showed O O
no O O
evidence O O
of O O
directional O O
mutation O O
. O O

Selenium O O
( O O
Se O O
) O O
- O O
fortified O O
broccoli B B_BIO
( O O
Brassica B B_LOCATION/B_ORGANIZATION
oleracea I I_LOCATION/I_ORGANIZATION
var I I_LOCATION/I_ORGANIZATION
. I I_LOCATION/I_ORGANIZATION
italica I I_LOCATION/I_ORGANIZATION
) O O
has O O
been O O
proposed O O
as O O
a O O
functional O O
food O O
for O O
cancer O O
prevention O O
, O O
based O O
on O O
its O O
high O O
glucosinolate O O
( O O
GSL O O
) O O
content O O
and O O
capacity O O
for O O
Se O O
accumulation O O
. O O

The O O
Perigord B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
black I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
truffle I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
responds O O
to O O
cold O O
temperature O O
with O O
an O O
extensive O O
reprogramming O O
of O O
its O O
transcriptional O O
activity O O
. O O

Porcine B B_VIRUS[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
endogenous I I_VIRUS[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
retroviruses I I_VIRUS[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
( O O
PERVs B B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
) O O
present O O
a O O
unique O O
concern O O
associated O O
with O O
xenotransplantation O O
because O O
they O O
have O O
been O O
shown O O
to O O
infect O O
certain O O
human B B_PERSON/B_SPECIES[BIO]
cells O O
in O O
vitro O O
and O O
it O O
is O O
also O O
difficult O O
to O O
generate O O
herds O O
of O O
pigs B B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
free O O
of O O
PERVs B B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

To O O
improve O O
the O O
MLV O O
- O O
based O O
retroviral B B_DISEASE/B_VIRUS[BIO]
vector O O
system O O
, O O
a O O
2 O O
. O O
1 O O
- O O
kb O O
PERV B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
- O O
B O O
env O O
product O O
was O O
amplified O O
from O O
PK O O
- O O
15 O O
genomic O O
DNA O O
and O O
cloned O O
into O O
the O O
pCL O O
- O O
Eco O O
retroviral O O
vector O O
. O O

The O O
titer O O
of O O
lacZ O O
( O O
PERV B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
B I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
from O O
the O O
293 O O
cells O O
was O O
about O O
1 O O
. O O
0x10 O O
( O O
4 O O
) O O
CFU O O
/ O O
ml O O
. O O

This O O
paper O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PRODUCT[OBJECT]
describes O O
the O O
morphology O B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
the O O
first O B_BIO/B_BODY_PART_OR_ORGAN_COMPONENT
cultivated O I_BIO/I_BODY_PART_OR_ORGAN_COMPONENT
strain O I_BIO/I_BODY_PART_OR_ORGAN_COMPONENT
of O O
Rhizomastix O B_BACTERIUM[BIO]
. O O

The O O
organism O B_BIO
was O O
isolated O O
from O O
an O O
argentine O B_BIO/B_LOCATION
horned O I_BIO/I_LOCATION
frog O I_BIO/I_LOCATION
and O O
differs O O
from O O
the O O
known O O
Rhizomastix O B_BIO/B_PERSON
species O I_BIO/I_PERSON
by O O
the O O
presence O B_LOCATION/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
biflagellate O B_BACTERIUM[BIO]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cells O B_BACTERIUM[BIO]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

A O O
possible O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
relationship O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
of O O
Rhizomastix O B_BACTERIUM[BIO]
to O O
Archamoebae O B_DISEASE/B_SPECIES[BIO]
is O O
discussed O O
. O O

The O O
validation O O
of O O
a O O
real O O
- O O
time O O
RT O O
- O O
PCR O O
assay O O
which O O
detects O O
influenza O O
A O O
and O O
types O O
simultaneously O O
for O O
influenza B B_DISEASE/B_MEASURE
A I I_DISEASE/I_MEASURE
H1N1 I I_DISEASE/I_MEASURE
( O O
2009 O O
) O O
and O O
oseltamivir O O
- O O
resistant O O
( O O
H275Y O O
) O O
influenza O O
A O O
H1N1 O O
( O O
2009 O O
) O O
. O O

It O O
was O O
the O O
aim O O
of O O
this O O
study O O
to O O
develop O O
a O O
real O O
- O O
time O O
RT O O
- O O
PCR O O
that O O
can O O
detect O O
all O O
influenza B B_BIO/B_GENE
A I I_BIO/I_GENE
viruses I I_BIO/I_GENE
and O O
type O O
simultaneously O O
for O O
influenza B B_DISEASE_ADJECTIVE[DISEASE]
A I I_DISEASE_ADJECTIVE[DISEASE]
H1N1 I I_DISEASE_ADJECTIVE[DISEASE]
( O O
2009 O O
) O O
and O O
oseltamivir O O
resistant O O
( O O
H275Y O O
) O O
influenza B B_DISEASE/B_PROTEIN[GENE]
A I B_DISEASE/I_PROTEIN[GENE]
H1N1 I B_DISEASE/I_PROTEIN[GENE]
( O O
2009 O O
) O O
. O O

This O O
multiplex O O
assay O O
will O O
allow O O
laboratories O O
to O O
screen O O
respiratory O O
samples O O
for O O
all O O
types O O
of O O
influenza B B_VIRUS[BIO]/B_DISEASE
A I I_VIRUS[BIO]/I_DISEASE
, O O
influenza B B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
A I B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
H1N1 I B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
( O O
2009 O O
) O O
virus O O
and O O
oseltamivir O O
resistant O O
( O O
H275Y O O
) O O
influenza B B_DISEASE/B_PROTEIN[GENE]
A I B_DISEASE/I_PROTEIN[GENE]
H1N1 I B_DISEASE/I_PROTEIN[GENE]
( O O
2009 O O
) O O
virus O O
in O O
a O O
rapid O O
and O O
cost O O
effective O O
format O O
, O O
ensuring O O
that O O
typing O O
methods O O
for O O
seasonal O O
and O O
avian O O
viruses O O
are O O
used O O
on O O
a O O
smaller O O
subset O O
of O O
samples O O
. O O

Neuropeptide O O
precursor O O
gene O O
discovery O O
in O O
the O O
Chagas O O
disease O O
vector O O
Rhodnius B B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
prolixus I B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
. O O

The O O
protein O O
kinase O O
found O O
in O O
the O O
short O O
region O O
of O O
alphaherpesviruses O O
, O O
termed O O
US3 O O
in O O
herpes B B_DISEASE/B_VIRUS[BIO]
simplex I B_DISEASE/I_VIRUS[BIO]
virus I B_DISEASE/I_VIRUS[BIO]
type I B_DISEASE/I_VIRUS[BIO]
1 I B_DISEASE/I_VIRUS[BIO]
( O O
HSV B B_VIRUS[BIO]/B_DISEASE
- I I_VIRUS[BIO]/I_DISEASE
1 I I_VIRUS[BIO]/I_DISEASE
) O O
and O O
pseudorabies B B_DISEASE/B_PROTEIN[GENE]
virus I B_DISEASE/I_PROTEIN[GENE]
( O O
PRV B B_PROTEIN[GENE]/B_DISEASE
) O O
and O O
ORF66 O O
in O O
varicella B B_DISEASE/B_VIRUS[BIO]
- I B_DISEASE/I_VIRUS[BIO]
zoster I B_DISEASE/I_VIRUS[BIO]
virus I B_DISEASE/I_VIRUS[BIO]
( O O
VZV B B_VIRUS[BIO]/B_DISEASE
) O O
, O O
affects O O
several O O
viral O O
and O O
host O O
cell O O
processes O O
, O O
and O O
its O O
specific O O
targets O O
remain O O
an O O
area O O
of O O
active O O
investigation O O
. O O

Reports O O
suggesting O O
that O O
HSV B B_DISEASE_ADJECTIVE[DISEASE]/B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
- I B_DISEASE_ADJECTIVE[DISEASE]/I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
1 I B_DISEASE_ADJECTIVE[DISEASE]/I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
US3 O O
substrates O O
overlap O O
with O O
those O O
of O O
cellular O O
protein O O
kinase O O
A O O
( O O
PKA O O
) O O
prompted O O
the O O
use O O
of O O
an O O
antibody O O
specific O O
for O O
phosphorylated O O
PKA O O
substrates O O
to O O
identify O O
US3 O O
/ O O
ORF66 O O
targets O O
. O O

The O O
predominant O O
VZV B B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
phosphorylated O O
125 O O
- O O
kDa O O
species O O
was O O
identified O O
as O O
matrin O O
3 O O
, O O
one O O
of O O
the O O
major O O
nuclear O O
matrix O O
proteins O O
. O O

Human B B_DISEASE
immunodeficiency I I_DISEASE
virus I I_DISEASE
type I I_DISEASE
1 I I_DISEASE
( O O
HIV B B_DISEASE
- I I_DISEASE
1 I I_DISEASE
) O O
infection O O
is O O
dependent O O
on O O
the O O
proper O O
disassembly O O
of O O
the O O
viral O O
capsid O O
, O O
or O O
& O O
quot O O
; O O
uncoating O O
, O O
& O O
quot O O
; O O
in O O
target O O
cells O O
. O O

We O O
describe O O
here O O
the O O
mechanism O O
of O O
action O O
of O O
a O O
small O O
molecule O O
HIV B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
1 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
inhibitor O O
, O O
PF O O
- O O
3450074 O O
( O O
PF74 O O
) O O
, O O
which O O
targets O O
CA O O
. O O

We O O
show O O
that O O
PF74 O O
binds O O
specifically O O
to O O
HIV B B_DISEASE/B_GENE
- I I_DISEASE/I_GENE
1 I I_DISEASE/I_GENE
particles O O
, O O
and O O
substitutions O O
in O O
CA O O
that O O
confer O O
resistance O O
to O O
the O O
compound O O
prevent O O
binding O O
. O O

Our O O
data O O
suggest O O
that O O
PF74 O O
triggers O O
premature O O
HIV B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
1 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
uncoating O O
in O O
target O O
cells O O
, O O
thereby O O
mimicking O O
the O O
activity O O
of O O
the O O
retrovirus O O
restriction O O
factor O O
TRIM5alpha O O
. O O

PB2 O O
residue O O
158 O O
is O O
a O O
pathogenic O O
determinant O O
of O O
pandemic O O
H1N1 B B_DISEASE/B_PROTEIN[GENE]
and O O
H5 B B_DISEASE/B_BIO
influenza I I_DISEASE/I_BIO
a I I_DISEASE/I_BIO
viruses I I_DISEASE/I_BIO
in O O
mice B B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

The O O
2009 O O
H1N1 B B_DISEASE
pandemic O O
was O O
caused O O
by O O
the O O
emergence O O
of O O
a O O
reassortant O O
H1N1 B B_DISEASE/B_PROTEIN[GENE]
subtype O O
( O O
H1N1pdm B B_DISEASE/B_PROTEIN[GENE]
) O O
influenza B B_DISEASE/B_GENE
A I B_DISEASE/I_GENE
virus I B_DISEASE/I_GENE
containing O O
gene O O
segments O O
that O O
originally O O
circulated O O
in O O
human B B_SPECIES[BIO]/B_LOCATION
, O O
avian O O
, O O
and O O
swine B B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
virus O O
reservoirs O O
. O O

The O O
molecular O O
determinants O O
of O O
replication O O
and O O
pathogenesis O O
of O O
H1N1pdm B B_DISEASE
viruses I I_DISEASE
in O O
humans B B_SPECIES[BIO]
and O O
other O O
mammals O O
are O O
poorly O O
understood O O
. O O

Our O O
data O O
also O O
show O O
that O O
PB2 O O
- O O
E158G O O
had O O
a O O
much O O
stronger O O
influence O O
on O O
the O O
RNA O O
replication O O
and O O
pathogenesis O O
of O O
H1N1pdm B B_DISEASE
viruses I I_DISEASE
than O O
PB2 O O
- O O
E627K O O
, O O
which O O
is O O
a O O
known O O
pathogenic O O
determinant O O
. O O

Remarkably O O
, O O
PB2 O O
- O O
E158G O O
substitutions O O
also O O
altered O O
the O O
pathotypes O O
of O O
two O O
avian O O
H5 B B_DISEASE/B_BIO
viruses I I_DISEASE/I_BIO
in O O
mice B B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
, O O
indicating O O
that O O
this O O
residue O O
impacts O O
genetically O O
divergent O O
influenza B B_BIO/B_DISEASE
A I I_BIO/I_DISEASE
viruses I I_BIO/I_DISEASE
and O O
suggesting O O
that O O
this O O
region O O
of O O
PB2 O O
could O O
be O O
a O O
new O O
antiviral O O
target O O
. O O

Hepatitis B B_DISEASE
C I I_DISEASE
virus I I_DISEASE
NS2 O O
protein O O
serves O O
as O O
a O O
scaffold O O
for O O
virus O O
assembly O O
by O O
interacting O O
with O O
both O O
structural O O
and O O
nonstructural O O
proteins O O
. O O

Many O O
aspects O O
of O O
the O O
assembly O O
of O O
hepatitis B B_DISEASE/B_VIRUS[BIO]
C I B_DISEASE/I_VIRUS[BIO]
virus I B_DISEASE/I_VIRUS[BIO]
( O O
HCV B B_DISEASE
) O O
remain O O
incompletely O O
understood O O
. O O

To O O
characterize O O
the O O
role O O
of O O
NS2 O O
in O O
the O O
production O O
of O O
infectious O O
virus O O
, O O
we O O
determined O O
NS2 O O
interaction O O
partners O O
among O O
other O O
HCV B B_DISEASE/B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
proteins O O
during O O
productive O O
infection O O
. O O

In O O
the O O
present O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
work O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
the O O
patterns O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
expression O B_GENE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
alcohol O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
dehydrogenase O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
a O O
typical O B_BACTERIUM[BIO]/B_ENZYME[GENE]
anaerobic O B_BACTERIUM[BIO]/I_ENZYME[GENE]
gene O B_BACTERIUM[BIO]/I_ENZYME[GENE]
in O O
plants O B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
of O O
the O O
hydrogenases O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
genes O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
HYD1 O B_PROTEIN[GENE]/B_DISEASE
, O O
HYD2 O B_PROTEIN[GENE]/B_DISEASE
) O O
and O O
of O O
the O O
genes O B_GENE/B_LOCATION
responsible O I_GENE/I_LOCATION
for O O
their O O
maturation O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
( O O
HYDEF O B_DISEASE/B_GENE
, O O
HYDG O B_PROTEIN[GENE]/B_DISEASE
) O O
, O O
were O O
analysed O O
. O O

Applied O O
biotechnology O O
for O O
production O O
of O O
immunoglobulin O O
Y O O
specific O O
to O O
hepatitis B B_DISEASE
A I I_DISEASE
virus I I_DISEASE
. O O

A O O
new O O
protocol O O
for O O
producing O O
polyclonal O O
antibody O O
against O O
hepatitis B B_DISEASE
A I I_DISEASE
virus I I_DISEASE
( O O
HAV B B_DISEASE
) O O
is O O
described O O
. O O

Twenty O O
hens B B_PERSON/B_SPECIES[BIO]
were O O
immunized O O
three O O
times O O
with O O
a O O
commercial O O
HAV B B_DISEASE/B_GENE
vaccine O O
and O O
HAV B B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
from O O
a O O
cell O O
culture O O
with O O
three O O
types O O
of O O
adjuvants O O
: O O
CpG O O
oligodeoxynucleotides O O
( O O
CpG O O
- O O
ODN O O
) O O
, O O
incomplete O O
Freund O O
' O O
s O O
adjuvant O O
and O O
an O O
alum O O
adjuvant O O
. O O

In O O
each O O
of O O
the O O
last O O
two O O
booster O O
inoculations O O
, O O
blood O O
from O O
the O O
birds O O
was O O
collected O O
and O O
tested O O
for O O
HAV B B_DISEASE
antibodies O O
. O O

After O O
the O O
first O O
immunization O O
, O O
birds O O
immunized O O
with O O
HAV B B_DISEASE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
from O O
cell O O
culture O O
plus O O
incomplete O O
Freund O O
' O O
s O O
adjuvant O O
with O O
/ O O
without O O
CpG O O
- O O
ODN O O
showed O O
highest O O
levels O O
of O O
anti O O
- O O
HAV B B_DISEASE
IgY O O
in O O
serum O O
( O O
p O O
& O O
lt O O
; O O
0 O O
. O O
05 O O
) O O
. O O

Viral O O
combination O O
with O O
CpG O O
- O O
ODN O O
resulted O O
in O O
early O O
response O O
of O O
anti O O
- O O
HAV B B_GENE/B_DISEASE
serum O O
in O O
hens B B_PERSON/B_SPECIES[BIO]
, O O
reflecting O O
the O O
amount O O
of O O
IgY O O
transferred O O
to O O
the O O
egg O O
yolk O O
( O O
p O O
& O O
lt O O
; O O
0 O O
. O O
05 O O
) O O
. O O

Uniquely O O
, O O
and O O
thus O O
used O O
to O O
diagnose O O
the O O
new O O
genus O O
Cotterillia B B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
, O O
it O O
has O O
dorsal O O
kineties O O
originating O O
de O O
novo O O
, O O
producing O O
neokinetal O O
waves O O
where O O
the O O
parental O O
dorsal O O
kineties O O
reorganize O O
to O O
& O O
quot O O
; O O
combined O O
rows O O
& O O
quot O O
; O O
, O O
consisting O O
of O O
dorsal O O
bristles O O
anteriorly O O
and O O
of O O
cirri O O
posteriorly O O
. O O

Interestingly O O
, O O
the O O
strongest O O
sequence O O
similarity O O
observed O O
was O O
between O O
the O O
partial O O
nod O O
sequences O O
of O O
Rhizobium B B_BIO
mongolense I I_BIO
USDA I I_BIO
1844 I I_BIO
and O O
the O O
corresponding O O
LPU83 B B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
nod O O
genes O O
sequences O O
. O O

The O O
phylogenetic O O
analysis O O
of O O
the O O
intergenic O O
region O O
nodEG O O
positions O O
strain O O
LPU83 B B_MEASURE
and O O
the O O
type O O
strain O O
R B B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. I I_LOCATION/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mongolense I I_LOCATION/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
1844 I I_LOCATION/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
the O O
same O O
branch O O
, O O
which O O
indicates O O
that O O
Rhizobium B B_PERSON/B_LOCATION
sp I I_PERSON/I_LOCATION
. I I_PERSON/I_LOCATION
strain I I_PERSON/I_LOCATION
LPU83 I I_PERSON/I_LOCATION
might O O
represent O O
an O O
early O O
alfalfa B B_PERSON/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
nodulating O O
genotype O O
. O O

The O O
NF O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
chemical O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
structures O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
obtained O O
for O O
the O O
wild O B_BIO
- O O
type O B_BIO/B_GENE
strain O I_BIO/I_GENE
consist O O
of O O
a O O
trimeric O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BACTERIUM[BIO]
, O O
tetrameric O B_BACTERIUM[BIO]/B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
and O O
pentameric O B_LOCATION/B_PROTEIN[GENE]
chitin O B_LOCATION/I_PROTEIN[GENE]
backbone O B_LOCATION/I_PROTEIN[GENE]
that O O
shares O O
some O O
substitutions O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
with O O
both O O
alfalfa O B_BIO/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
and O O
bean O B_BIO/B_DISEASE
- O O
nodulating O O
rhizobia O B_BIO/B_PROTEIN[GENE]
. O O

Remarkably O O
, O O
while O O
in O O
strain O O
LPU83 B B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
most O O
of O O
the O O
NFs O O
were O O
sulfated O O
in O O
their O O
reducing O O
terminal O O
residue O O
, O O
none O O
of O O
the O O
NFs O O
isolated O O
from O O
the O O
nodH O O
mutant O O
LPU83 B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
- I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
H I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
were O O
sulfated O O
. O O

The O O
evidence O O
obtained O O
supports O O
the O O
notion O O
that O O
the O O
sulfate O O
decoration O O
of O O
NFs O O
in O O
LPU83 B B_BIO/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O O
not O O
necessary O O
for O O
alfalfa B B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
nodulation O O
. O O

The O O
enterobacterial O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BACTERIUM[BIO]
common O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BACTERIUM[BIO]
antigen O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BACTERIUM[BIO]
( O O
ECA O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
) O O
is O O
a O O
highly O O
conserved O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
exopolysaccharide O I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
in O O
Gram O B_BACTERIUM[BIO]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
negative O B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
bacteria O I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
whose O O
role O B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
remains O O
largely O O
uncharacterized O B_DISEASE_ADJECTIVE[DISEASE]/B_BACTERIUM[BIO]
. O O

These O O
results O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
provide O O
a O O
new O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
perspective O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
from O O
which O O
to O O
understand O O
the O O
phylogenetic O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
conservation O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
ECA O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
among O O
enterobacteria O B_BACTERIUM[BIO]
and O O
the O O
basis O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
for O O
the O O
virulence O B_DISEASE_ADJECTIVE[DISEASE]
attenuation O I_DISEASE_ADJECTIVE[DISEASE]
detected O O
in O O
wec O B_DISEASE_ADJECTIVE[DISEASE]/B_BIO
mutant O I_DISEASE_ADJECTIVE[DISEASE]/I_BIO
strains O I_DISEASE_ADJECTIVE[DISEASE]/I_BIO
in O O
other O B_BIO
pathogenic O I_BIO
bacteria O I_BIO
. O O

The O O
increased O O
level O B_MEASURE
of O O
urease O B_BACTERIUM[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
in O O
gastric O B_DISEASE_ADJECTIVE[DISEASE]/B_BIO
acidity O B_DISEASE_ADJECTIVE[DISEASE]/I_BIO
is O O
due O B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
, O O
in O O
part O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
to O O
acid O O
activation O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
of O O
the O O
two O B_NUMBER[MEASURE]/B_DISEASE
- O O
component O B_LOCATION/B_PERSON
system O I_LOCATION/I_PERSON
( O O
TCS O B_DISEASE/B_LOCATION
) O O
consisting O O
of O O
the O O
membrane O B_ENZYME[GENE]
sensor O I_ENZYME[GENE]
HP0165 O I_ENZYME[GENE]
and O O
its O O
response O B_GENE/B_PERSON
regulator O I_GENE/I_PERSON
, O O
HP0166 O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
which O O
regulates O O
transcription O B_NUMBER[MEASURE]/B_GENE
of O O
the O O
seven O B_GENE/B_MEASURE
genes O I_GENE/I_MEASURE
of O O
the O O
urease O B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
gene O B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
cluster O B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
. O O

We O O
now O O
find O O
that O O
there O O
are O O
two O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
major O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
ureAB O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
transcripts O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
: O O
a O O
2 O B_MEASURE
. O O
7 O B_MEASURE
- O O
kb O B_MEASURE/B_LOCATION
full O I_MEASURE/I_LOCATION
- O O
length O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
ureAB O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
transcript O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O O
a O O
1 O B_MEASURE
. O O
4 O B_MEASURE
- O O
kb O B_GENE/B_MEASURE
truncated O B_GENE/I_MEASURE
transcript O B_GENE/I_MEASURE
lacking O O
3 O B_NUMBER[MEASURE]
' O O
ureB O B_BACTERIUM[BIO]/B_GENE
. O O

Northern O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
blot O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
analysis O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
with O O
sense O B_DISEASE_ADJECTIVE[DISEASE]/B_BIO
RNA O I_DISEASE_ADJECTIVE[DISEASE]/I_BIO
and O O
strand O B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
- O O
specific O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
oligonucleotide O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
probes O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
followed O O
by O O
5 O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
' O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
rapid O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
amplification O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
cDNA O B_GENE
ends O I_GENE
detects O O
an O O
antisense O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
small O I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
RNA O I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
sRNA O B_GENE/B_BIO
) O O
encoded O O
by O O
the O O
5 O B_NUMBER[MEASURE]
' O O
ureB O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
noncoding O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
strand O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
consisting O O
of O O
- O O
290 O B_MEASURE
nucleotides O I_MEASURE
( O O
5 O B_NUMBER[MEASURE]
' O O
ureB O B_BACTERIUM[BIO]/B_LOCATION
- O O
sRNA O B_GENE/B_BIO
) O O
. O O

Deletion O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
HP0165 O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
elevates O O
the O O
level O B_MEASURE/B_LOCATION
of O O
the O O
truncated O O
1 O B_MEASURE
. O O
4 O B_MEASURE
- O O
kb O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
transcript O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
along O O
with O O
that O O
of O O
the O O
5 O B_MEASURE
' O O
ureB O B_BACTERIUM[BIO]/B_DISEASE
- O O
sRNA O B_GENE/B_BIO
at O O
both O O
pH O B_MEASURE
7 O I_MEASURE
. O O
4 O B_MEASURE
and O O
pH O B_MEASURE
4 O I_MEASURE
. O O
5 O B_MEASURE
. O O

Overexpression O B_GENE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
5 O B_MEASURE/B_LOCATION
' O O
ureB O B_BACTERIUM[BIO]/B_PROTEIN[GENE]
- O O
sRNA O B_GENE/B_BIO
increases O O
the O O
1 O B_MEASURE
. O O
4 O B_MEASURE
- O O
kb O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
transcript O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
decreases O O
the O O
2 O B_MEASURE
. O O
7 O B_MEASURE
- O O
kb O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
transcript O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
and O O
decreases O O
urease O B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
activity O I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Non O O
- O O
structural O O
protein O O
1 O O
( O O
NS1 O O
) O O
antibody O O
- O O
based O O
assays O O
to O O
differentiate O O
West B B_DISEASE
Nile I I_DISEASE
( O O
WN O O
) O O
virus O O
from O O
Japanese O O
encephalitis O O
virus O O
infections O O
in O O
horses O O
: O O
effects O O
of O O
WN B B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
virus I B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
NS1 O O
antibodies O O
induced O O
by O O
inactivated O O
WN O O
vaccine O O
. O O

However O O
, O O
since O O
the O O
inactivated O O
West O O
Nile O O
( O O
WN B B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
vaccine O O
has O O
been O O
reported O O
to O O
induce O O
NS1 O O
antibodies O O
, O O
there O O
is O O
concern O O
about O O
the O O
reliability O O
of O O
using O O
NS1 O O
- O O
based O O
assays O O
for O O
testing O O
vaccinated O O
horses O O
. O O

Therefore O O
, O O
the O O
effect O O
of O O
inactivated O O
WN B B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
vaccine O O
- O O
induced O O
antibodies O O
on O O
an O O
epitope O O
- O O
blocking O O
ELISA O O
and O O
complement O O
- O O
dependent O O
cytotoxicity O O
( O O
CDC O O
) O O
assay O O
were O O
investigated O O
. O O

High O O
- O O
titer O O
autologous O O
neutralizing O O
antibody O O
responses O O
have O O
been O O
demonstrated O O
during O O
early O O
subtype O O
C O O
human B B_DISEASE/B_VIRUS[BIO]
immunodeficiency I B_DISEASE/I_VIRUS[BIO]
virus I B_DISEASE/I_VIRUS[BIO]
type I B_DISEASE/I_VIRUS[BIO]
1 I B_DISEASE/I_VIRUS[BIO]
( O O
HIV B B_DISEASE
- I I_DISEASE
1 I I_DISEASE
) O O
infection O O
. O O

Here O O
, O O
the O O
novel O O
orf B B_VIRUS[BIO]/B_DISEASE
virus I I_VIRUS[BIO]/I_DISEASE
( O O
ORFV B B_VIRUS[BIO]
) O O
- O O
encoded O O
protein O O
ORFV002 B B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
was O O
shown O O
to O O
inhibit O O
nuclear O O
events O O
regulating O O
NF O O
- O O
kappaB O O
transcriptional O O
activity O O
. O O

ORFV002 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
expression O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
in O O
cell O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
cultures O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
significantly O O
decreased O O
wild O B_VIRUS[BIO]/B_DISEASE
- O O
type O B_DISEASE/B_MEASURE
- O O
virus O B_GENE/B_BIO
- O O
, O O
tumor O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
necrosis O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
factor O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
alpha O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O O
TNF O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
alpha O B_PROTEIN[GENE]/B_LOCATION
) O O
- O O
, O O
and O O
lipopolysaccharide O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
LPS O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
- O O
induced O O
NF O B_DISEASE/B_GENE
- O O
kappaB O B_PROTEIN[GENE]/B_LOCATION
- O O
mediated O O
gene O B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
expression O I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Noroviruses O B_BACTERIUM[BIO]/B_PERSON
are O O
the O O
principal O B_DISEASE_ADJECTIVE[DISEASE]/B_BIO
cause O I_DISEASE_ADJECTIVE[DISEASE]/I_BIO
of O O
epidemic O B_DISEASE
gastroenteritis O I_DISEASE
worldwide O I_DISEASE
. O O

Surrogate O O
neutralization O O
assays O O
using O O
sera O O
from O O
outbreaks O O
and O O
from O O
immunized O O
mice O O
suggest O O
that O O
, O O
as O O
with O O
influenza B B_DISEASE
virus I I_DISEASE
, O O
antigenic O O
variation O O
maintains O O
GII O O
. O O
4 O O
persistence O O
in O O
the O O
face O O
of O O
human B B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
population O O
herd O O
immunity O O
. O O

To O O
test O O
this O O
hypothesis O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
, O O
mice O B_SPECIES[BIO]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
hyperimmunized O O
with O O
virus O B_VIRUS[BIO]/B_DISEASE
- O O
like O B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
particles O I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
VLPs O B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
) O O
representing O O
an O O
early O B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
( O O
GII O B_TIME[MEASURE]/B_PROTEIN[GENE]
. O O
4 O B_NUMBER[MEASURE]
- O O
1987 O B_MEASURE
) O O
and O O
a O O
contemporary O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
( O O
GII O B_MEASURE/B_DISEASE
. O O
4 O B_MEASURE
- O O
2006 O B_MEASURE
) O O
GII O B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
. O O
4 O B_MEASURE
strain O I_MEASURE
. O O

As O O
with O O
influenza B B_DISEASE
virus I I_DISEASE
, O O
HIV O O
, O O
and O O
hepatitis B B_DISEASE
C I I_DISEASE
virus I I_DISEASE
, O O
norovirus O O
antigenic O O
variation O O
will O O
significantly O O
influence O O
the O O
design O O
of O O
efficacious O O
vaccines O O
and O O
immunotherapeutics O O
against O O
these O O
important O O
human B B_SPECIES[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
pathogens O O
. O O

Vesicular B B_VIRUS[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
stomatitis I I_VIRUS[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
virus I I_VIRUS[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
( O O
VSV B B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
) O O
is O O
a O O
rhabdovirus O O
that O O
alters O O
host O O
nuclear O O
and O O
cytoplasmic O O
function O O
upon O O
infection O O
. O O

These O O
data O O
illustrate O O
that O O
VSV B B_DISEASE/B_GENE
utilizes O O
a O O
novel O O
mechanism O O
to O O
alter O O
this O O
central O O
player O O
in O O
cell O O
signaling O O
and O O
oncogenesis O O
. O O

It O O
also O O
suggests O O
an O O
inside O O
- O O
out O O
model O O
of O O
signal O O
transduction O O
where O O
VSV B B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
interruption O O
of O O
nuclear O O
events O O
has O O
a O O
rapid O O
and O O
significant O O
effect O O
on O O
membrane O O
signaling O O
events O O
. O O

Activation O O
of O O
plasmacytoid O O
dendritic O O
cells O O
by O O
Kaposi B B_DISEASE/B_GENE
' I B_DISEASE/I_GENE
s I B_DISEASE/I_GENE
sarcoma I B_DISEASE/I_GENE
- I B_DISEASE/I_GENE
associated I B_DISEASE/I_GENE
herpesvirus I B_DISEASE/I_GENE
. O O

Infection O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
with O O
one O B_DISEASE
serotype O I_DISEASE
likely O O
elicits O O
lifelong O B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
immunity O B_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
that O O
serotype O B_BACTERIUM[BIO]/B_DISEASE
, O O
but O O
generally O O
not O O
against O O
the O O
other O B_NUMBER[MEASURE]/B_PERSON
three O B_NUMBER[MEASURE]/I_PERSON
. O O

Dengue B B_DISEASE
infection O O
, O O
although O O
frequently O O
mild O O
, O O
can O O
lead O O
to O O
dengue B B_DISEASE_ADJECTIVE[DISEASE]
hemorrhagic O O
fever O O
( O O
DHF O O
) O O
which O O
can O O
be O O
life O O
threatening O O
. O O

This O O
has O O
important O O
implications O O
for O O
dengue B B_DISEASE
vaccine O O
design O O
because O O
heterologous O O
boosting O O
is O O
likely O O
to O O
maintain O O
the O O
immunological O O
footprint O O
of O O
the O O
first O O
vaccination O O
. O O

On O O
the O O
basis O O
of O O
these O O
findings O O
, O O
we O O
propose O O
a O O
simple O O
in O O
vitro O O
enzyme O O
- O O
linked O O
immunosorbent O O
assay O O
( O O
ELISA O O
) O O
to O O
diagnose O O
the O O
original O O
dengue B B_DISEASE
infection O O
in O O
secondary O O
dengue B B_DISEASE/B_PERSON
cases O O
. O O

One O O
- O O
step O O
real O O
- O O
time O O
reverse O O
transcription O O
- O O
PCR O O
assays O O
for O O
detecting O O
and O O
subtyping O O
pandemic B B_DISEASE/B_LOCATION
influenza I I_DISEASE/I_LOCATION
A I I_DISEASE/I_LOCATION
/ I I_DISEASE/I_LOCATION
H1N1 I I_DISEASE/I_LOCATION
2009 I I_DISEASE/I_LOCATION
, O O
seasonal B B_MEASURE/B_DISEASE
influenza I I_MEASURE/I_DISEASE
A I I_MEASURE/I_DISEASE
/ I I_MEASURE/I_DISEASE
H1N1 I I_MEASURE/I_DISEASE
, O O
and O O
seasonal B B_DISEASE/B_LOCATION
influenza I I_DISEASE/I_LOCATION
A I I_DISEASE/I_LOCATION
/ I I_DISEASE/I_LOCATION
H3N2 I I_DISEASE/I_LOCATION
viruses I I_DISEASE/I_LOCATION
. O O

Pandemic B B_DISEASE
influenza I I_DISEASE
A I I_DISEASE
/ I I_DISEASE
H1N1 I I_DISEASE
2009 I I_DISEASE
( I I_DISEASE
A I I_DISEASE
/ I I_DISEASE
H1N1pdm I I_DISEASE
) I I_DISEASE
virus I I_DISEASE
has O O
caused O O
significant O O
outbreaks O O
worldwide O O
. O O

To O O
help O O
with O O
the O O
screening O O
of O O
the O O
A B B_DISEASE/B_BIO
/ I B_DISEASE/I_BIO
H1N1pdm I B_DISEASE/I_BIO
virus I B_DISEASE/I_BIO
, O O
rRT O O
- O O
PCR O O
assays O O
were O O
also O O
developed O O
for O O
detecting O O
human B B_DISEASE/B_PROTEIN[GENE]
seasonal B B_DISEASE/I_PROTEIN[GENE]
A I B_DISEASE/I_PROTEIN[GENE]
/ I B_DISEASE/I_PROTEIN[GENE]
H1N1 I B_DISEASE/I_PROTEIN[GENE]
( O O
H1 O O
rRT O O
- O O
PCR O O
assay O O
) O O
and O O
A B B_DISEASE/B_PROTEIN[GENE]
/ I B_DISEASE/I_PROTEIN[GENE]
H3N2 I B_DISEASE/I_PROTEIN[GENE]
influenza I B_DISEASE/I_PROTEIN[GENE]
viruses I B_DISEASE/I_PROTEIN[GENE]
( O O
H3 O O
rRT O O
- O O
PCR O O
assay O O
) O O
. O O

H1pdm O B_PROTEIN[GENE]
, O O
H1 O O
, O O
and O O
H3 O B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
rRT O I_PROTEIN[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
PCR O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
assays O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
were O O
evaluated O O
using O O
in O O
vitro O B_LOCATION
- O O
transcribed O O
control O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
RNA O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
isolated O B_VIRUS[BIO]/B_GENE
viruses O B_VIRUS[BIO]/I_GENE
, O O
and O O
other O B_BIO/B_GENE
respiratory O B_BIO/I_GENE
pathogenic O B_BIO/I_GENE
viruses O B_BIO/I_GENE
, O O
and O O
were O O
shown O O
to O O
have O O
high O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sensitivity O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
good O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
linearity O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
( O O
R O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
( O O
2 O B_MEASURE/B_LOCATION
) O O
= O O
0 O B_MEASURE
. O O
99 O B_MEASURE
) O O
, O O
and O O
high O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
specificity O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

In O O
addition O O
, O O
the O O
improved O O
H1pdm O O
rRT O O
- O O
PCR O O
assay O O
could O O
detect O O
two O O
viral B B_DISEASE/B_BIO
strains I B_DISEASE/I_BIO
of I B_DISEASE/I_BIO
A I B_DISEASE/I_BIO
/ I B_DISEASE/I_BIO
H1N1pdm I B_DISEASE/I_BIO
, O O
namely O O
, O O
A B B_DISEASE/B_PROTEIN[GENE]
/ I B_DISEASE/I_PROTEIN[GENE]
Aichi I B_DISEASE/I_PROTEIN[GENE]
/ I B_DISEASE/I_PROTEIN[GENE]
472 I B_DISEASE/I_PROTEIN[GENE]
/ I B_DISEASE/I_PROTEIN[GENE]
2009 I B_DISEASE/I_PROTEIN[GENE]
( I B_DISEASE/I_PROTEIN[GENE]
H1N1 I B_DISEASE/I_PROTEIN[GENE]
) I B_DISEASE/I_PROTEIN[GENE]
pdm I B_DISEASE/I_PROTEIN[GENE]
and O O
A B B_DISEASE/B_PROTEIN[GENE]
/ I B_DISEASE/I_PROTEIN[GENE]
Sakai I B_DISEASE/I_PROTEIN[GENE]
/ I B_DISEASE/I_PROTEIN[GENE]
89 I B_DISEASE/I_PROTEIN[GENE]
/ I B_DISEASE/I_PROTEIN[GENE]
2009 I B_DISEASE/I_PROTEIN[GENE]
( I B_DISEASE/I_PROTEIN[GENE]
H1N1 I B_DISEASE/I_PROTEIN[GENE]
) I B_DISEASE/I_PROTEIN[GENE]
pdm I B_DISEASE/I_PROTEIN[GENE]
, O O
which O O
have O O
mutation O O
( O O
s O O
) O O
in O O
the O O
probe O O
- O O
binding O O
region O O
of O O
the O O
hemagglutinin O O
gene O O
, O O
without O O
loss O O
of O O
sensitivity O O
. O O

Of O O
these O O
, O O
26 O O
, O O
20 O O
, O O
and O O
2 O O
samples O O
were O O
identified O O
as O O
positive O O
for O O
A B B_PROTEIN[GENE]/B_DISEASE
/ I I_PROTEIN[GENE]/I_DISEASE
H1pdm I I_PROTEIN[GENE]/I_DISEASE
, O O
A B B_PROTEIN[GENE]/B_DISEASE
/ I I_PROTEIN[GENE]/I_DISEASE
H3 I I_PROTEIN[GENE]/I_DISEASE
, O O
and O O
A B B_GENE/B_VIRUS[BIO]
/ I B_GENE/I_VIRUS[BIO]
H1 I B_GENE/I_VIRUS[BIO]
, O O
respectively O O
, O O
while O O
42 O O
samples O O
were O O
negative O O
for O O
influenza B B_VIRUS[BIO]/B_PROTEIN[GENE]
A I B_VIRUS[BIO]/I_PROTEIN[GENE]
viruses I B_VIRUS[BIO]/I_PROTEIN[GENE]
. O O

The O O
KingFisher O O
mL O O
and O O
easyMAG O O
protocols O O
provided O O
1 O O
- O O
to O O
3 O O
- O O
log O O
wider O O
linearity O O
and O O
extracted O O
3 O O
- O O
to O O
4 O O
- O O
fold O O
more O O
RNA O O
from O O
the O O
human B B_VIRUS[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
influenza I I_VIRUS[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
virus I I_VIRUS[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
and O O
respiratory B B_DISEASE/B_GENE
syncytial I B_DISEASE/I_GENE
virus I B_DISEASE/I_GENE
. O O

Suppressor O B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/B_GENE
mutations O I_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/I_GENE
in O O
the O O
prfB O B_BACTERIUM[BIO]/B_GENE
and O O
prfC O B_GENE/B_BIO
genes O I_GENE/I_BIO
encoding O O
release O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
factor O I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
2 O I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
RF2 O B_GENE/B_LOCATION
) O O
and O O
RF3 O B_GENE
that O O
restore O O
the O O
wild O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
type O B_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- O O
growth O B_MEASURE/B_BIO
rate O B_MEASURE/I_BIO
and O O
also O O
correct O O
the O O
ribosomal O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
defects O I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
have O O
now O O
been O O
isolated O O
. O O

However O O
, O O
further O O
genetic O O
analysis O O
reported O O
here O O
also O O
reveals O O
that O O
the O O
slow O O
growth O O
and O O
other O O
defects O O
associated O O
with O O
inactivation O O
of O O
rluD O O
in O O
E B B_DISEASE_ADJECTIVE[DISEASE]/B_NUMBER[MEASURE]
. I I_DISEASE_ADJECTIVE[DISEASE]/I_NUMBER[MEASURE]
coli I I_DISEASE_ADJECTIVE[DISEASE]/I_NUMBER[MEASURE]
K I I_DISEASE_ADJECTIVE[DISEASE]/I_NUMBER[MEASURE]
- I I_DISEASE_ADJECTIVE[DISEASE]/I_NUMBER[MEASURE]
12 I I_DISEASE_ADJECTIVE[DISEASE]/I_NUMBER[MEASURE]
strains O O
are O O
due O O
to O O
a O O
defective O O
RF2 O O
protein O O
, O O
with O O
a O O
threonine O O
at O O
position O O
246 O O
, O O
which O O
is O O
present O O
in O O
all O O
K B B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
- I B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
12 I B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
strains O O
. O O

Alphacoronavirus O O
transmissible B B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
gastroenteritis I B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
virus I B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
nsp1 O O
protein O O
suppresses O O
protein O O
translation O O
in O O
mammalian O O
cells O O
and O O
in O O
cell O O
- O O
free O O
HeLa O O
cell O O
extracts O O
but O O
not O O
in O O
rabbit B B_SPECIES[BIO]/B_DISEASE
reticulocyte O O
lysate O O
. O O

Modification O O
of O O
nonstructural O O
protein O O
1 O O
of O O
influenza B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
A I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
virus I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
by O O
SUMO1 O O
. O O

In O O
this O O
study O O
, O O
the O O
effects O O
of O O
atmospheric O O
CO O O
( O O
2 O O
) O O
availability O O
on O O
the O O
transcriptome O O
, O O
proteome O O
and O O
metabolome O O
profiles O O
of O O
two O O
ranks O O
of O O
source O O
leaves O O
in O O
maize B B_BIO
( O O
Zea B B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
mays I B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
L O O
. O O
) O O
were O O
studied O O
in O O
plants O O
grown O O
under O O
ambient O O
CO O O
( O O
2 O O
) O O
conditions O O
( O O
350 O O
+ O O
/ O O
- O O
20 O O
muL O O
L O O
( O O
- O O
1 O O
) O O
CO O O
( O O
2 O O
) O O
) O O
or O O
with O O
CO O O
( O O
2 O O
) O O
enrichment O O
( O O
700 O O
+ O O
/ O O
- O O
20 O O
muL O O
L O O
( O O
- O O
1 O O
) O O
CO O O
( O O
2 O O
) O O
) O O
. O O

Chlamydia O B_BACTERIUM[BIO]
spp O I_BACTERIUM[BIO]
. O O
are O O
medically O O
important O B_DISEASE_ADJECTIVE[DISEASE]/B_BACTERIUM[BIO]
bacteria O I_DISEASE_ADJECTIVE[DISEASE]/I_BACTERIUM[BIO]
and O O
encode O O
an O O
atypical O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
OmpR O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
/ O O
PhoB O B_LOCATION/B_BACTERIUM[BIO]
subfamily O O
response O B_GENE/B_TIME[MEASURE]
regulator O I_GENE/I_TIME[MEASURE]
termed O O
ChxR O B_GENE/B_DISEASE
. O O

In O O
Salmonella O B_SPECIES[BIO]
, O O
the O O
Salmonella O B_BACTERIUM[BIO]/B_GENE
pathogenicity O B_BACTERIUM[BIO]/I_GENE
island O B_BACTERIUM[BIO]/I_GENE
1 O B_BACTERIUM[BIO]/I_GENE
( O O
SPI O B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
1 O B_NUMBER[MEASURE]
) O O
encodes O B_GENE/B_MEASURE
a O O
type O B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
three O I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
secretion O I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
system O I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
, O O
which O O
is O O
required O O
for O O
invasion O B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANISM_FUNCTION
of O O
host O B_BACTERIUM[BIO]/B_DISEASE
epithelial O I_BACTERIUM[BIO]/I_DISEASE
cells O I_BACTERIUM[BIO]/I_DISEASE
in O O
the O O
small O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
intestine O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
. O O

One O B_NUMBER[MEASURE]/B_PERSON
known O O
regulator O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
of O O
hilA O B_BACTERIUM[BIO]/B_DISEASE
is O O
Fur O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
. O O

The O O
Fur O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O O
dependent O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
regulation O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O O
hilA O B_BACTERIUM[BIO]/B_GENE
was O O
independent O B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
of O O
PhoP O B_GENE/B_BACTERIUM[BIO]
, O O
a O O
known O O
repressor O B_GENE/B_PERSON
of O O
hilA O B_BACTERIUM[BIO]/B_GENE
. O O

The O O
type O B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
III O I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
secretion O I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
system O I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
( O O
T3SS O B_DISEASE/B_LOCATION
) O O
is O O
the O O
most O O
important O B_DISEASE_ADJECTIVE[DISEASE]/B_BACTERIUM[BIO]
virulence O I_DISEASE_ADJECTIVE[DISEASE]/I_BACTERIUM[BIO]
factor O I_DISEASE_ADJECTIVE[DISEASE]/I_BACTERIUM[BIO]
in O O
Pseudomonas O B_BACTERIUM[BIO]
aeruginosa O I_BACTERIUM[BIO]
, O O
and O O
its O O
expression O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
level O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
varies O O
in O O
different O B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
isolates O I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
. O O

This O O
property O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
makes O O
it O O
a O O
good O B_BACTERIUM[BIO]/B_PERSON
starting O I_BACTERIUM[BIO]/I_PERSON
microorganism O I_BACTERIUM[BIO]/I_PERSON
for O O
further O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANISM_FUNCTION
development O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANISM_FUNCTION
toward O O
a O O
bioremediation O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
tool O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
. O O

Resting O O
cells O O
of O O
strain O O
IL1403 B B_PROTEIN[GENE]
( O O
pFL3 O O
) O O
rapidly O O
consumed O O
citrate O O
while O O
producing O O
acetoin O O
when O O
substoichiometric O O
concentrations O O
of O O
glucose O O
or O O
l O O
- O O
lactate O O
were O O
present O O
. O O

Tracking O O
a O O
century O O
of O O
global O O
expansion O O
and O O
evolution O O
of O O
HIV B B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
drive O O
understanding O O
and O O
to O O
combat O O
disease O O
. O O

Assessment O O
of O O
samples O O
from O O
apes O O
and O O
human B B_PERSON/B_SPECIES[BIO]
beings O O
with O O
African O O
equatorial O O
forest O O
ancestry O O
has O O
traced O O
the O O
origin O O
of O O
HIV B B_SPECIES[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
- I I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
1 I I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
to O O
chimpanzees B B_MEASURE/B_LOCATION
, O O
and O O
dated O O
its O O
most O O
recent O O
common O O
ancestor O O
to O O
1908 O O
. O O

The O O
evolution O O
of O O
HIV B B_DISEASE
- I I_DISEASE
1 I I_DISEASE
has O O
been O O
rapid O O
, O O
which O O
has O O
resulted O O
in O O
a O O
complex O O
classification O O
, O O
worldwide O O
spread O O
, O O
and O O
intermixing O O
of O O
strains O O
; O O
at O O
least O O
48 O O
circulating O O
recombinant O O
forms O O
are O O
currently O O
identified O O
. O O

Previously O O
, O O
the O O
electron O B_GENE/B_DISEASE
transfer O I_GENE/I_DISEASE
flavoproteins O I_GENE/I_DISEASE
EtfA O I_GENE/I_DISEASE
and O O
EtfB O B_BACTERIUM[BIO]/B_GENE
were O O
found O O
to O O
be O O
involved O O
in O O
caffeate O B_DISEASE_ADJECTIVE[DISEASE]
respiration O I_DISEASE_ADJECTIVE[DISEASE]
. O O

By O O
inverse O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
PCR O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
we O O
identified O O
three O B_GENE/B_LOCATION
genes O I_GENE/I_LOCATION
upstream O O
of O O
etfA O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BACTERIUM[BIO]
and O O
etfB O B_BACTERIUM[BIO]/B_DISEASE
: O O
carA O B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
carB O B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
and O O
carC O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
. O O

P B B_DISEASE/B_GENE
. I B_DISEASE/I_GENE
aeruginosa I B_DISEASE/I_GENE
contains O O
two O O
different O O
sugar O O
chains O O
, O O
the O O
homopolymer O O
common O O
antigen O O
( O O
A O O
band O O
) O O
and O O
the O O
heteropolymer O O
O O O
antigen O O
( O O
B O O
band O O
) O O
, O O
which O O
impart O O
serospecificity O O
. O O

Major O B_PERSON/B_LOCATION
subunits O I_PERSON/I_LOCATION
constitute O O
the O O
pilus O B_BACTERIUM[BIO]/B_GENE
backbone O B_BACTERIUM[BIO]/I_GENE
and O O
are O O
therefore O O
essential O B_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
for O O
pilus O B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANISM_FUNCTION
formation O I_DISEASE_ADJECTIVE[DISEASE]/I_ORGANISM_FUNCTION
. O O

In O O
accordance O B_TIME[MEASURE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O O
the O O
current O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
model O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
of O O
pilus O B_BACTERIUM[BIO]/B_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]
assembly O B_BACTERIUM[BIO]/I_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]
by O O
Gram O B_BACTERIUM[BIO]/B_GENE
- O O
positive O B_DISEASE_ADJECTIVE[DISEASE]/B_BIO
organisms O B_DISEASE_ADJECTIVE[DISEASE]/I_BIO
, O O
the O O
major O B_GENE
subunit O I_GENE
Sgp1 O I_GENE
was O O
indispensable O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
for O O
backbone O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]
formation O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]
and O O
the O O
cognate O B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
sortase O I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
SrtG O I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
mediated O O
the O O
polymerization O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]
of O O
both O O
subunits O B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
. O O

However O O
, O O
unlike O O
other O B_NUMBER[MEASURE]/B_LOCATION
well O O
- O O
characterized O O
Gram O B_BACTERIUM[BIO]/B_GENE
- O O
positive O B_DISEASE_ADJECTIVE[DISEASE]/B_BIO
bacterial O I_DISEASE_ADJECTIVE[DISEASE]/I_BIO
pili O I_DISEASE_ADJECTIVE[DISEASE]/I_BIO
, O O
the O O
minor O B_GENE
subunit O I_GENE
Sgp2 O I_GENE
was O O
required O O
for O O
polymerization O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]
of O O
the O O
major O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
subunit O B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Sgp1 O B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Because O O
Sgp2 O B_PERSON/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
homologues O I_PERSON/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
are O O
encoded O O
in O O
several O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
other O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
Gram O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
- O O
positive O B_DISEASE_ADJECTIVE[DISEASE]/B_BIO
bacterial O B_DISEASE_ADJECTIVE[DISEASE]/I_BIO
pilus O B_DISEASE_ADJECTIVE[DISEASE]/I_BIO
gene O B_DISEASE_ADJECTIVE[DISEASE]/I_BIO
clusters O B_DISEASE_ADJECTIVE[DISEASE]/I_BIO
, O O
in O O
some O O
types O B_PERSON/B_DISEASE
of O O
pili O B_BACTERIUM[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
, O O
minor O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
pilin O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
subunits O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
may O O
contribute O O
to O O
backbone O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
formation O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
by O O
a O O
novel O B_LOCATION/B_ENZYME[GENE]
mechanism O B_LOCATION/I_ENZYME[GENE]
. O O

Tuberculosis O O
, O O
malaria O O
, O O
filariasis O O
, O O
visceral O O
leishmaniasis O O
, O O
leprosy O O
, O O
HIV B B_DISEASE
infection O O
, O O
and O O
childhood O O
cluster O O
of O O
vaccine O O
- O O
preventable O O
diseases O O
are O O
given O O
priority O O
for O O
control O O
through O O
centrally O O
managed O O
vertical O O
programmes O O
. O O

Control O O
of O O
HIV B B_DISEASE
infection O O
and O O
leprosy O O
, O O
but O O
not O O
of O O
tuberculosis O O
, O O
seems O O
to O O
be O O
on O O
track O O
. O O

Other O O
infectious O O
diseases O O
caused O O
by O O
faecally O O
transmitted O O
pathogens O O
( O O
enteric O O
fevers O O
, O O
cholera O O
, O O
hepatitis B B_DISEASE/B_PROTEIN[GENE]
A I B_DISEASE/I_PROTEIN[GENE]
and O O
E B B_VIRUS[BIO]/B_LOCATION
viruses I I_VIRUS[BIO]/I_LOCATION
) O O
and O O
zoonoses O O
( O O
rabies O O
, O O
leptospirosis O O
, O O
anthrax O O
) O O
are O O
not O O
in O O
the O O
process O O
of O O
being O O
systematically O O
controlled O O
. O O

The O O
problem O O
stems O O
from O O
environmental O O
factors O O
that O O
promote O O
tobacco B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
use O O
, O O
unhealthy O O
diet O O
, O O
and O O
inadequate O O
physical O O
activity O O
. O O

We O O
investigated O O
the O O
effect O O
of O O
pH O O
on O O
the O O
competition O O
of O O
two O O
closely O O
related O O
chrysomonad O O
species O O
, O O
Poterioochromonas B B_LOCATION/B_NUMBER[MEASURE]
malhamensis I B_LOCATION/I_NUMBER[MEASURE]
originating O O
from O O
circumneutral O O
Lake O O
Constance O O
, O O
and O O
Ochromonas O O
sp O O
. O O
isolated O O
from O O
a O O
highly O O
acidic O O
mining O O
lake O O
in O O
Austria O O
( O O
pH O O
- O O
2 O O
. O O
6 O O
) O O
. O O

We O O
tested O O
the O O
hypothesis O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
that O O
the O O
acidotolerant O B_BACTERIUM[BIO]
species O O
benefits O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
from O O
competitive O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANISM_FUNCTION
release O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANISM_FUNCTION
under O O
conditions O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
acid O B_DISEASE_ADJECTIVE[DISEASE]
stress O I_DISEASE_ADJECTIVE[DISEASE]
. O O

The O O
neutrophilic O B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
strain O B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
numerically O O
dominated O O
over O O
the O O
acidotolerant O B_BACTERIUM[BIO]/B_MEASURE
strain O I_BACTERIUM[BIO]/I_MEASURE
at O O
pH O B_MEASURE
7 O I_MEASURE
. O O
0 O B_MEASURE
, O O
but O O
was O O
the O O
inferior O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
competitor O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
at O O
pH O B_MEASURE
2 O I_MEASURE
. O O
5 O B_MEASURE
. O O

Wolbachia O B_BACTERIUM[BIO]
and O O
Cardinium O B_SPECIES[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
are O O
bacterial O B_BIO
endosymbionts O I_BIO
that O O
are O O
widely O O
distributed O O
amongst O B_BIO/B_LOCATION
arthropods O B_BIO/I_LOCATION
. O O

Host O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
immune O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
responses O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
differed O O
, O O
possibly O O
because O O
of O O
the O O
different O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cell O I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
wall O I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
structures O I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
Wolbachia O B_BACTERIUM[BIO]
and O O
Cardinium O B_DISEASE_ADJECTIVE[DISEASE]/B_TIME[MEASURE]
because O O
the O O
former O B_BIO/B_DISEASE
lacks O O
genes O B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
encoding O O
lipopolysaccharide O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
components O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O O
two O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
racemases O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
for O O
peptidoglycan O B_DISEASE_ADJECTIVE[DISEASE]
formation O I_DISEASE_ADJECTIVE[DISEASE]
. O O

1 O B_NUMBER[MEASURE]
, O O
Metaracoelophrya O B_BACTERIUM[BIO]
sp O I_LOCATION
. O O

2 O O
, O O
Metaracoelophrya B B_MEASURE/B_PERSON
intermedia I I_MEASURE/I_PERSON
, O O
Metaradiophrya O O
sp O O
. O O
, O O
Njinella B B_NUMBER[MEASURE]
prolifera I I_NUMBER[MEASURE]
, O O
Paraclausilocola B B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
constricta I I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
n I I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
. I I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
gen I I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
. I I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
, I I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
n I I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
. I I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
sp I I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
. I I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
and O O
Paraclausilocola B B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
elongata I I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
n I I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
. I I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
sp I I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
. I I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]

The O O
nine O B_BIO/B_PERSON
species O I_BIO/I_PERSON
of O O
astomes O B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
formed O O
a O O
strongly O O
supported O O
clade O B_BIO/B_LOCATION
, O O
showing O O
the O O
subclass O B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
Astomatia O I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
to O O
be O O
monophyletic O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
and O O
a O O
weakly O O
supported O O
sister O B_PERSON/B_BIO
clade O I_PERSON/I_BIO
to O O
the O O
scuticociliates O B_BACTERIUM[BIO]/B_MEASURE
. O O

Juvenile O O
Atlantic B B_SPECIES[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
salmon I I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
( O O
Salmo B B_DISEASE/B_LOCATION
salar I B_DISEASE/I_LOCATION
) O O
of O O
different O O
age O O
classes O O
exhibit O O
different O O
behavioural O O
responses O O
to O O
elevated O O
temperatures O O
( O O
> O O
23 O O
^ O O
0C O O
) O O
. O O

Three O B_NUMBER[MEASURE]/B_BIO
lineages O I_NUMBER[MEASURE]/I_BIO
- O O
the O O
Bacillariales O B_SPECIES[BIO]/B_PERSON
, O O
Rhopalodiales O B_BACTERIUM[BIO]/B_PERSON
, O O
and O O
Surirellales O B_BACTERIUM[BIO]
- O O
possess O O
a O O
complex O B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
presumably O O
highly O O
derived O O
raphe O B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O O
is O O
physically O O
separated O O
from O O
the O O
cell O B_BODY_PART_OR_ORGAN_COMPONENT/B_PERSON
interior O B_BODY_PART_OR_ORGAN_COMPONENT/I_PERSON
, O O
most O O
often O O
by O O
a O O
set O B_GENE/B_LOCATION
of O O
siliceous O B_DISEASE_ADJECTIVE[DISEASE]/B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
braces O B_DISEASE_ADJECTIVE[DISEASE]/I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
. O O

The O O
canal O B_LOCATION/B_DISEASE
raphe O I_LOCATION/I_DISEASE
appears O O
to O O
have O O
evolved O O
twice O O
, O O
once O O
in O O
the O O
common O B_PERSON/B_BIO
ancestor O I_PERSON/I_BIO
of O O
Bacillariales O B_SPECIES[BIO]
and O O
once O O
in O O
the O O
common O B_PERSON/B_BIO
ancestor O I_PERSON/I_BIO
of O O
Rhopalodiales O B_BACTERIUM[BIO]
and O O
Surirellales O B_SPECIES[BIO]/B_LOCATION
, O O
which O O
form O O
a O O
monophyletic O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
group O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
in O O
our O O
analyses O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

We O O
used O O
27 O O
years O O
of O O
longitudinal O O
data O O
collected O O
on O O
tawny B B_LOCATION/B_DISEASE_ADJECTIVE[DISEASE]
owls I I_LOCATION/I_DISEASE_ADJECTIVE[DISEASE]
with O O
estimates O O
of O O
prey O O
density O O
( O O
field O O
voles O O
) O O
from O O
Kielder O O
Forest O O
( O O
UK O O
) O O
to O O
investigate O O
how O O
prey O O
density O O
at O O
birth O O
affects O O
ageing O O
patterns O O
in O O
reproduction O O
and O O
survival O O
. O O

Because O O
of O O
the O O
high O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
mortality O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
, O O
the O O
fulminant O B_DISEASE/B_MEASURE
course O I_DISEASE/I_MEASURE
, O O
and O O
the O O
refractoriness O B_DISEASE_ADJECTIVE[DISEASE]
to O O
common O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
treatment O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
overwhelming O B_DISEASE
infections O I_DISEASE
caused O O
by O O
encapsulated O B_BACTERIUM[BIO]/B_DISEASE
bacteria O I_BACTERIUM[BIO]/I_DISEASE
, O O
prevention O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
through O O
vaccination O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
and O O
antibiotic O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
prophylaxis O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
is O O
the O O
basis O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O O
the O O
management O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
patients O B_PERSON
who O O
have O O
had O O
splenectomy O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
or O O
have O O
hyposplenism O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

The O O
Lancet O O
NCD O O
Action O O
Group O O
and O O
the O O
NCD O O
Alliance O O
propose O O
five O O
overarching O O
priority O O
actions O O
for O O
the O O
response O O
to O O
the O O
crisis O O
- O O
- O O
leadership O O
, O O
prevention O O
, O O
treatment O O
, O O
international O O
cooperation O O
, O O
and O O
monitoring O O
and O O
accountability O O
- O O
- O O
and O O
the O O
delivery O O
of O O
five O O
priority O O
interventions O O
- O O
- O O
tobacco B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
control O O
, O O
salt O O
reduction O O
, O O
improved O O
diets O O
and O O
physical O O
activity O O
, O O
reduction O O
in O O
hazardous O O
alcohol O O
intake O O
, O O
and O O
essential O O
drugs O O
and O O
technologies O O
. O O

The O O
most O O
urgent O O
and O O
immediate O O
priority O O
is O O
tobacco B B_ORGANIZATION/B_DISEASE
control O O
. O O

We O O
propose O O
as O O
a O O
goal O O
for O O
2040 O O
, O O
a O O
world O O
essentially O O
free O O
from O O
tobacco B B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
where O O
less O O
than O O
5 O O
% O O
of O O
people O O
use O O
tobacco O O
. O O

The O O
mec1Delta O B_PROTEIN[GENE]/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ O O
Delta O B_PROTEIN[GENE]/B_BIO
colonies O I_PROTEIN[GENE]/I_BIO
have O O
a O O
wild O B_BIO/B_BODY_PART_OR_ORGAN_COMPONENT
- O O
type O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
colony O B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
morphology O B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
, O O
while O O
the O O
sgs1Delta O B_GENE/B_DISEASE
/ O O
Delta O B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
mutants O I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
are O O
slow O O
- O O
growing O O
, O O
producing O O
wrinkled O O
colonies O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
with O O
pseudohyphal O B_BACTERIUM[BIO]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
- O O
like O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
cells O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
. O O

Tortricid O O
moths O O
reared O O
from O O
the O O
invasive O O
weed O O
Mexican B B_BIO
palo I I_BIO
verde I I_BIO
, O O
Parkinsonia B B_LOCATION
aculeata I I_LOCATION
, O O
with O O
comments O O
on O O
their O O
host O O
specificity O O
, O O
biology O O
, O O
geographic O O
distribution O O
, O O
and O O
systematics O O
. O O

As O O
part O O
of O O
efforts O O
to O O
identify O O
native O O
herbivores O O
of O O
Mexican B B_LOCATION
palo I I_LOCATION
verde I I_LOCATION
, O O
Parkinsonia B B_PERSON
aculeata I I_PERSON
L O O
. O O

( O O
both O O
Tortricinae O B_BIO/B_PERSON
: O O
Cochylini O B_LOCATION/B_PERSON
) O O
, O O
Ofatulena O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
duodecemstriata O I_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
Walsingham O B_LOCATION/B_PERSON
) O O
, O O
O O O
. O O
luminosa O B_PERSON
Heinrich O I_PERSON
, O O
Ofatulena O B_BACTERIUM[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sp O I_LOCATION
. O O

( O O
all O O
Olethreutinae O B_BIO/B_PERSON
: O O
Grapholitini O B_BACTERIUM[BIO]/B_LOCATION
) O O
, O O
and O O
Crocidosema O B_LOCATION/B_BIO
lantana O I_LOCATION/I_BIO
Busck O I_LOCATION/I_BIO
( O O
Olethreutinae O B_BIO/B_LOCATION
: O O
Eucosmini O B_LOCATION/B_PERSON
) O O
. O O

Wolbachia O O
wSinvictaA B B_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
infections O O
in O O
natural O O
populations O O
of O O
the O O
fire B B_SPECIES[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
ant I I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
Solenopsis B I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
invicta I I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
: O O
testing O O
for O O
phenotypic O O
effects O O
. O O

Wolbachia O B_BACTERIUM[BIO]/B_PERSON
are O O
intracellular O B_SPECIES[BIO]
bacteria O I_SPECIES[BIO]
that O O
commonly O O
infect O O
many O B_SPECIES[BIO]
arthropods O I_SPECIES[BIO]
and O O
some O O
nematodes O B_BIO/B_DISEASE
. O O

Previous O O
studies O O
have O O
demonstrated O O
that O O
individuals O O
from O O
native O O
populations O O
of O O
the O O
invasive O O
fire B B_LOCATION/B_DISEASE_ADJECTIVE[DISEASE]
ant I I_LOCATION/I_DISEASE_ADJECTIVE[DISEASE]
Solenopsis B I_LOCATION/I_DISEASE_ADJECTIVE[DISEASE]
invicta I I_LOCATION/I_DISEASE_ADJECTIVE[DISEASE]
commonly O O
harbor O O
one O O
or O O
more O O
of O O
three O O
Wolbachia O O
variants O O
. O O

In O O
order O O
to O O
determine O O
the O O
phenotypic O O
effects O O
and O O
likely O O
population O O
dynamics O O
of O O
wSinvictaA B B_SPECIES[BIO]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
infections O O
in O O
these O O
ants O O
, O O
brood O O
production O O
patterns O O
of O O
newly O O
mated O O
fire B B_BIO/B_PERSON
ant I I_BIO/I_PERSON
queens O O
were O O
studied O O
during O O
simulated O O
claustral O O
founding O O
and O O
measured O O
wSinvictaA B B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
transmission O O
fidelity O O
within O O
mature O O
single O O
- O O
queen O O
families O O
. O O

Fungi O B_BACTERIUM[BIO]/B_PERSON
, O O
particularly O O
some O O
members O B_PERSON/B_BIO
of O O
the O O
Ascomycota O B_BIO/B_PERSON
, O O
are O O
likely O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
candidates O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
for O O
biocontrol O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
agents O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
against O O
these O O
insect O B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
pests O I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
, O O
but O O
several O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
studies O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
revealed O O
their O O
failure O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
invade O O
the O O
insect O B_BIO/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cuticle O I_BIO/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
possibly O O
because O O
of O O
the O O
presence O B_LOCATION/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
inhibitory O B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
compounds O I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
such O I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
as O O
phenols O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
, O O
quinones O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
, O O
and O O
lipids O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
and O O
also O O
by O O
the O O
antibiosis O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
effect O I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O O
the O O
microbiota O B_BACTERIUM[BIO]
living O O
on O O
the O O
cuticular O B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
surface O B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
of O O
the O O
host O B_BIO
. O O

Among O O
the O O
most O O
effective O O
antagonistic O O
strains O O
, O O
six O O
isolates O O
of O O
Bacillus B B_BACTERIUM[BIO]/B_PERSON
thuringiensis I I_BACTERIUM[BIO]/I_PERSON
Berliner O O
( O O
Bacillales O O
: O O
Bacillaeae O O
( O O
after O O
B B B_MEASURE
. I I_MEASURE
subtilis I I_MEASURE
) O O
) O O
, O O
one O O
isolate O O
of O O
B B B_BACTERIUM[BIO]/B_PERSON
. I I_BACTERIUM[BIO]/I_PERSON
mycoides I I_BACTERIUM[BIO]/I_PERSON
Flugge O O
, O O
eight O O
isolates O O
of O O
B B B_PERSON/B_BACTERIUM[BIO]
. I I_PERSON/I_BACTERIUM[BIO]
megaterium I I_PERSON/I_BACTERIUM[BIO]
de O O
Bary O O
, O O
five O O
isolates O O
of O O
B B B_BACTERIUM[BIO]
. I I_BACTERIUM[BIO]
pumilus I I_BACTERIUM[BIO]
Meyer O O
and O O
Gottheil O O
, O O
one O O
isolate O O
of O O
B B B_BACTERIUM[BIO]/B_PERSON
. I I_BACTERIUM[BIO]/I_PERSON
licheniformis I I_BACTERIUM[BIO]/I_PERSON
( O O
Weigmann O O
) O O
Chester O O
, O O
and O O
four O O
isolates O O
of O O
B B B_BACTERIUM[BIO]/B_PERSON
. I I_BACTERIUM[BIO]/I_PERSON
subtilis I I_BACTERIUM[BIO]/I_PERSON
( O O
Ehrenberg O O
) O O
Cohn O O
were O O
identified O O
. O O

Morphological O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
differences O B_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
molecular O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
phylogeny O I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
of O O
freshwater O B_LOCATION/B_BIO
blooming O O
species O B_BIO
, O O
Peridiniopsis O B_BACTERIUM[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
spp O O
. O O

Furthermore O O
it O O
was O O
concluded O O
that O O
the O O
endosymbionts O B_BIO
might O O
originate O O
from O O
Discostella O B_BACTERIUM[BIO]
- O O
like O B_BIO
species O I_BIO
. O O

HaTHY O B_GENE
was O O
able O B_DISEASE_ADJECTIVE[DISEASE]
to O O
be O O
upregulated O O
by O O
20 O B_MEASURE
- O O
hydroxyecdysone O B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
or O O
by O O
bacterial O B_BACTERIUM[BIO]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
viral O B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
challenge O B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

To O O
better O O
characterize O O
these O O
mechanisms O O
, O O
we O O
identified O O
a O O
conidiation O O
- O O
defective O O
mutant O O
, O O
ATMT0225B6 B B_DISEASE/B_LOCATION
( O O
MoCDC15 B B_PROTEIN[GENE]/B_BIO
( I I_PROTEIN[GENE]/I_BIO
T I I_PROTEIN[GENE]/I_BIO
- I I_PROTEIN[GENE]/I_BIO
DNA I I_PROTEIN[GENE]/I_BIO
) I I_PROTEIN[GENE]/I_BIO
) O O
, O O
in O O
which O O
a O O
T O O
- O O
DNA O O
insertion O O
disrupted O O
a O O
gene O O
that O O
encodes O O
a O O
homolog O O
of O O
fission O O
yeast B B_SPECIES[BIO]/B_GENE
cdc15 O O
, O O
and O O
generated O O
a O O
second O O
strain O O
containing O O
a O O
disruption O O
in O O
the O O
same O O
allele O O
( O O
DeltaMoCDC15 O O
( O O
T O O
- O O
DNA O O
) O O
) O O
. O O

All O O
phenotypic O O
defects O O
observed O O
in O O
mutants O O
were O O
rescued O O
in O O
a O O
strain O O
complemented O O
with O O
wild B B_GENE
type I I_GENE
MoCDC15 I I_GENE
. O O

Species O O
identity O O
and O O
trichothecene O O
toxin O O
potential O O
of O O
560 O O
members O O
of O O
the O O
Fusarium B B_BIO/B_LOCATION
graminearum I I_BIO/I_LOCATION
species I I_BIO/I_LOCATION
complex I I_BIO/I_LOCATION
( O O
FGSC B B_DISEASE/B_LOCATION
) O O
collected O O
from O O
diseased O O
wheat B B_BIO
, O O
barley B B_BIO
and O O
maize B B_BIO
in O O
South O O
Africa O O
was O O
determined O O
using O O
a O O
microsphere O O
- O O
based O O
multilocus O O
genotyping O O
assay O O
. O O

A O O
significant O O
difference O O
, O O
however O O
, O O
was O O
identified O O
in O O
the O O
composition O O
of O O
FGSC B B_DISEASE_ADJECTIVE[DISEASE]/B_NUMBER[MEASURE]
pathogens O O
associated O O
with O O
Gibberella O O
ear O O
rot O O
( O O
GER O O
) O O
of O O
maize B B_BIO
as O O
compared O O
to O O
Fusarium O O
head O O
blight O O
( O O
FHB O O
) O O
of O O
wheat B B_BIO
or O O
barley B B_BIO
( O O
P O O
& O O
lt O O
; O O
0 O O
. O O
001 O O
) O O
. O O

Medium O O
M O O
, O O
which O O
favoured O O
growth O O
of O O
both O O
protozoa O O
species O O
, O O
was O O
tested O O
again O O
and O O
Epidinium B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
ecaudatum I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
was O O
included O O
. O O

Infraciliature O O
of O O
eight O O
Triplumaria O O
species O O
( O O
Ciliophora O O
, O O
Entodiniomorphida O O
) O O
from O O
Asian B B_LOCATION
elephants I I_LOCATION
with O O
the O O
description O O
of O O
six O O
new O O
species O O
. O O

sp O B_LOCATION/B_PERSON
. O O
, O O
T O B_OTHER/B_GENE
. O O
solea O B_BACTERIUM[BIO]/B_LOCATION
n O I_LOCATION
. O O

Ciliate O B_BACTERIUM[BIO]/B_MEASURE
densities O I_BACTERIUM[BIO]/I_MEASURE
in O O
the O O
three O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
fecal O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
samples O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
were O O
0 O B_MEASURE
. O O
15 O B_MEASURE
, O O
1 O B_MEASURE
. O O
09 O B_MEASURE
, O O
and O O
2 O B_MEASURE
. O O
07x10 O B_MEASURE
( O O
4 O B_MEASURE/B_LOCATION
) O O
/ O O
ml O B_MEASURE/B_PERSON
. O O

Development O O
Time O O
and O O
Body O O
Size O O
in O O
Eupolyphaga B B_LOCATION
sinensis I I_LOCATION
Along O O
a O O
Latitudinal O O
Gradient O O
From O O
China O O
. O O

Culture O O
Independent O O
Survey O O
of O O
the O O
Microbiota O O
of O O
the O O
Glassy B B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_SPECIES[BIO]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Winged I I_SPECIES[BIO]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Sharpshooter I I_SPECIES[BIO]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
Homalodisca B B_MEASURE/B_DISEASE
vitripennis I I_MEASURE/I_DISEASE
) O O
Using O O
454 O O
Pyrosequencing O O
. O O

